Orbifloxacin: A Review of Properties, Its Antibacterial Activities, Pharmacokinetic/Pharmacodynamic Characteristics, Therapeutic Use, and Analytical Methods

Orbifloxacin is a third generation of fluoroquinolone that exhibits increased antibacterial activity against the Enterobacteriaceae, gram-negative and gram-positive bacteria, anaerobes, and mycobacteria. This drug was synthesized in 1987 and developed as a veterinary chemotherapeutic to use for livestock and domestic pets. Orbifloxacin is labeled for the treatment of skin, soft tissue, and urinary tract infections in dogs, and skin and soft tissue infections in cats, but in some countries, orbifloxacin has been given for the treatment of gastrointestinal and respiratory infections in cattle and swine and other animals. The in vitro activity and clinical efficacy of orbifloxacin against naturally occurring bacterial infections of the skin, ear, soft tissue, udder, and gastrointestinal and respiratory systems in different animals have been evaluated and good responses have been found. The minimum inhibitory concentration of orbifloxacin has been determined in various different pathogens and the results found in the literature are shown in this work. The pharmacokinetics of orbifloxacin has been evaluated by different routes of administration in goats, horses, pigs, rabbits, dogs, cats, camels, cattle, sheep, and fish. Orbifloxacin exhibits excellent pharmacokinetic parameters that suggest that this drug may have good clinical effects on various bacterial infections in these species. All methods described in the scientific literature for determination of orbifloxacin in different matrices were collected and discussed. © 2013 Copyright Taylor and Francis Group, LLC.

Photodynamic inactivation of biofilm: Taking a lightly colored approach to stubborn infection

Microbial biofilms are responsible for a variety of microbial infections in different parts of the body, such as urinary tract infections, catheter infections, middle-ear infections, gingivitis, caries, periodontitis, orthopedic implants, and so on. The microbial biofilm cells have properties and gene expression patterns distinct from planktonic cells, including phenotypic variations in enzymic activity, cell wall composition and surface structure, which increase the resistance to antibiotics and other antimicrobial treatments. There is consequently an urgent need for new approaches to attack biofilm-associated microorganisms, and antimicrobial photodynamic therapy (aPDT) may be a promising candidate. aPDT involves the combination of a nontoxic dye and low-intensity visible light which, in the presence of oxygen, produces cytotoxic reactive oxygen species. It has been demonstrated that many biofilms are susceptible to aPDT, particularly in dental disease. This review will focus on aspects of aPDT that are designed to increase efficiency against biofilms modalities to enhance penetration of photosensitizer into biofilm, and a combination of aPDT with biofilm-disrupting agents. © 2013 Informa UK Ltd.

Análise químico-farmacêutica de norflocacino comprimidos e estudos de complexação com β-Ciclodextrina e polimorfismo

Pós-graduação em Ciências Farmacêuticas - FCFAR

Análise químico-farmacêutica de preparações injetáveis contendo ceftazidima

Pós-graduação em Ciências Farmacêuticas - FCFAR

Análise qualitativa e quantitativa de cefoxitina sódica em injetáveis: desenvolvimento e validação de métodos analíticos e estudo de estabilidade

Pós-graduação em Ciências Farmacêuticas - FCFAR

Desenvolvimento e avaliação de um modelo de assistência contínuo, paliativo e domiciliar a pacientes com câncer mamário ou ginecológico fora de possibilidade de cura

Pós-graduação em Ginecologia, Obstetrícia e Mastologia - FMB

Infecções do trato urinário e do trato genital inferior em gestantes de baixo risco do município de Botucatu/SP

Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)

Identificação de Enterococcus spp. e avaliação da ocorrência de genes de resistência á vancomicina em amostras de pacientes de hospitais de manaus, AM

Pós-graduação em Fisiopatologia em Clínica Médica - FMB

Análise químico-farmacêutica de preparações injetáveis de Aztreonam

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)

Prevalence of uropathogens and antimicrobial susceptibility profile in outpatient from Jataí-GO

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Overlapped Sequence Types (STs) and Serogroups of Avian Pathogenic (APEC) and Human Extra-Intestinal Pathogenic (ExPEC) Escherichia coli Isolated in Brazil

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Estudo fitoquímico e propriedades biológicas da Dipteryx alata Vogel (baru)

Pós-graduação em Ciência dos Materiais - FEIS

Detecção e caracterização de Escherichia coli potencialmente patogênicas em aves selvagens e pombos-domésticos na cidade de Jaboticabal-SP

Pós-graduação em Microbiologia Agropecuária - FCAV

Perfil de suscetibilidade, genes de resistência aos aminoglicosídeos e similaridade genética em amostras de Acinetobacter baumannii isoladas em um Hospital Terciário

Pós-graduação em Microbiologia - IBILCE

Infecção do trato urinário adquirida em ambiente hospitalar em idosos

Introduction: Hospital-acquired urinary tract infection (HAUTI) is an important cause of morbidity in the elderly population. Objective: Evaluate the occurrence of HAUTI and risk factors associated with it. Method: This is a prospective study of a sample of 332 elderly people, interned in a university hospital. Criteria for defining infection were established by the Center for Diseases and Prevention Control. Statistical analysis of data used calculation of frequencies, odds ratio and logistic regression. The rate of hospital infection was 23.6%. The prevalent topographies of infection were respiratory infections (27.6%), urinary tract infections (26.4%) and surgical wound infections (23.6%, with 21, 20 and 19 episodes, respectively. The HAUTI incidence density associated with urinary catheterization was 24.2 infections by 1,000 catheter-days. The length of hospital stay of patients without nosocomial infection was 6.9 days and with HAUTI was increased in 10.4 (p<0.05).The rate of mortality of patients with HAUTI was 20%. Pathogens were isolated in 75% of episodes of HAUTI and the prevalent were: Escherichia coli (33%) and Pseudomonas aeruginosa (20%). Risk factors found for HAUTI were urinary catheterization implementation (odds ratio (OR) = 43.1; 95% confidence interval (95 CI%) = 3.9 – 311.1), hospitalization with community infection (OR= 21.9; 95% CI = 4.9 – 97.9); vascular diseases (OR=14; 95% CI = 2 – 98); diabetes mellitus (OR= 5.5; 95% CI = 1.4 – 21) and urinary catheterization by more than three days (OR=3.7; 95% CI = 1 – 13.8). Conclusions: HAUTI presented elevated incidence and it increased the length of hospital stay.